Skip to main content

Day: February 14, 2023

Garrett Motion Reports Fourth Quarter 2022 Financial Results

Fourth Quarter 2022 HighlightsReported net sales totaled $898 million, up 4% on a GAAP basis, up 15% at constant currency* Net income totaled $112 million; Net income margin 12.5% Adjusted EBITDA* totaled $140 million; Adjusted EBITDA margin* of 15.6% Net cash provided by operating activities totaled $137 million Adjusted free cash flow* totaled $132 millionYTD 2022 HighlightsNet sales totaled $3,603 million, down 1% on a GAAP basis, up 8% at constant currency* Net income totaled $390 million; Net Income Margin 10.8% Adjusted EBITDA* was $570 million; Adjusted EBITDA margin* was 15.8% Net cash provided by operating activities totaled $375 million Adjusted free cash flow* totaled $313 million Delivered outlook for 2022ROLLE, Switzerland, Feb. 14, 2023 (GLOBE NEWSWIRE) — Garrett Motion Inc. (Nasdaq: GTX, GTXAP), a leading...

Continue reading

Descartes Acquires GroundCloud

Strengthens Final-Mile Carrier Capabilities and Adds Road Safety Compliance Platform WATERLOO, Ontario, Feb. 14, 2023 (GLOBE NEWSWIRE) — Descartes Systems Group (TSX:DSG) (Nasdaq:DSGX), the global leader in uniting logistics-intensive businesses in commerce, announced that it has acquired GroundCloud, a cloud-based provider of final-mile carrier solutions and road safety compliance tools. GroundCloud is a leader in final-mile logistics automation, combining operations, safety and compliance in an integrated platform. Final-mile carriers leverage the platform to receive customer delivery orders, plan and execute routes against those orders, train and monitor drivers on safety and performance, manage assets and resources, and analyze the operating efficiency of their business. GroundCloud’s platform also incorporates video telematics...

Continue reading

Form 8.5 (EPT/RI) – Kape Technologies Plc

FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)   1.        KEY INFORMATION  (a)        Name of exempt principal trader: Shore Capital Stockbrokers Ltd(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Kape Technologies Plc(c)        Name of the party to the offer with which exempt principal trader is connected: Kape Technologies Plc(d)        Date dealing undertaken: 13 February 2023(e)        Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer? No  2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER   (a)        Purchases...

Continue reading

Armada Hoffler Reports Fourth Quarter and Full Year 2022 Results

Net Income of $0.13 per Diluted Share for the Fourth Quarter and $0.94 per Diluted Share for the Full Year Normalized FFO of $0.35 per Diluted Share for the Fourth Quarter and $1.22 per Diluted Share for the Full Year, Representing a 13% Year-Over-Year Increase Earns BBB Investment Grade Credit Rating Introduces 2023 Full-Year Normalized FFO Guidance Range of $1.23 to $1.27 per Diluted Share VIRGINIA BEACH, Va., Feb. 14, 2023 (GLOBE NEWSWIRE) — Armada Hoffler Properties, Inc. (NYSE: AHH) today announced its results for the quarter and year ended December 31, 2022 and provided an update on current events. Highlights include:Net income attributable to common stockholders and OP Unit holders of $11.5 million, or $0.13 per diluted share, for the quarter ended December 31, 2022 compared to $0.4 million, or less than $0.01 per diluted...

Continue reading

Patria Reports Fourth Quarter & Full Year 2022 Earnings Results

GRAND CAYMAN, Cayman Islands, Feb. 14, 2023 (GLOBE NEWSWIRE) — Patria (Nasdaq:PAX) reported today its unaudited results for the fourth quarter and full year ended December 31, 2022. The full detailed presentation of Patria’s fourth quarter and full year 2022 results can be accessed on the Shareholders section of Patria’s website at https://ir.patria.com/. Alex Saigh, Patria’s CEO, said: “Patria generated strong results for the 4th quarter and full year 2022, delivering our FRE guidance for 50% annual growth, as well as performance fees during a challenging year for global markets. We believe we are uniquely positioned as a gateway for alternative investments in Latin America, with the talent and resources in place to execute on the multi-year targets shared at our recent Investor Day event.” Financial Highlights (reported...

Continue reading

Grocery Outlet Holding Corp. Announces Fourth Quarter and Fiscal 2022 Earnings Release and Conference Call Date

EMERYVILLE, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) — Grocery Outlet Holding Corp. (NASDAQ: GO) (“Grocery Outlet”) today announced that its financial results for the fourth quarter and full fiscal 2022 year will be released after the market close on Tuesday, February 28, 2023. The company will host a conference call at 4:30pm ET (1:30pm PT) to discuss the results. Investors and analysts interested in joining the call are invited to dial (877) 407-9208 approximately 10 minutes prior to the start of the call, using conference ID #13730480. A live audio webcast of the conference call will be available online at https://investors.groceryoutlet.com. A taped replay of the conference call will be available within two hours of the conclusion of the call and can be accessed online or by dialing (844) 512-2921 and entering access code 13730480....

Continue reading

Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia

BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolemia (HeFH) under the Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory body of the United Kingdom (UK). The ILAP aims to accelerate time to market and facilitate patient access to innovative medicines. VERVE-101 is a novel, investigational gene editing medicine designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver to durably lower disease-driving low-density lipoprotein...

Continue reading

Embecta Corp. Reports First Quarter Fiscal 2023 Financial Results

PARSIPPANY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) — Embecta Corp. (“embecta” or the “Company”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today reported financial results for the three month period ended December 31, 2022. “We are pleased with our financial performance in the first fiscal quarter, which exceeded our initial expectations in an operating environment that remains challenging,” said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta. “During fiscal year 2023, we remain focused on three key strategic priorities: strengthening our base business, separating and standing up embecta as an independent company, and investing in growth. Throughout the first quarter, we made progress on each of these objectives, as we continue setting up embecta for...

Continue reading

Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs

WATERTOWN, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it has entered into a securities purchase agreement with certain investors resulting in an aggregate $62.5 million in gross proceeds through a registered direct offering. The financing was led by Bain Capital Life Sciences, who contributed $50 million, with participation from existing investors, Access Biotechnology and OrbiMed. The financing includes 1,488,166 shares of the Company’s common stock at a price of $23.00 per share and pre-funded warrants to purchase up to an aggregate of 1,229,224 shares of common stock, at a purchase price of $22.9999,...

Continue reading

TransUnion Announces Fourth Quarter 2022 Results

Total revenues increased by 14 percent (2 percent organic constant currency revenue growth excluding mortgage) driven by strength in International Drove strong results with recent acquisitions, notably Neustar revenue grew 8 percent compared to its fourth quarter 2021 Completed sale of non-core businesses (G2, LCI and Fintellix) for $176 million of consideration Prepaid $200 million in debt in fourth quarter of 2022 for a total of $600 million in 2022 Providing 2023 financial guidance, we expect to deliver 3 to 5 percent revenue growthCHICAGO, Feb. 14, 2023 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) (the “Company”) today announced financial results for the quarter ended December 31, 2022. Fourth Quarter 2022 Results Revenue:Total revenue for the quarter was $902 million, an increase of 14 percent (17 percent on a constant...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.